ADCs as biological missiles for targeted therapies
Explore the market growth of ADCs, innovations in the ADC space, and the future of ADCs as a targeted therapy for various diseases, including cancer.
Antibody Drug Conjugates: Re-emergence of an old modality for targeted therapies
Explore the key challenges in ADC development and how Syngene, a leading CRO/CDMO, is supporting clients in the discovery, development, and manufacturing of innovative ADC molecules.
How Syngene enabled an emerging pharma company to develop an innovative drug to treat erectile dysfunction
Learn how Syngene transitioned a drug meant for treating erectile dysfunction from late-phase discovery to early-phase clinical studies for an emerging pharma company.
How to overcome solubility challenges by applying amorphous solid dispersion: An end-to-end solution
Discover the successful approach to preparing, screening, characterizing, and dosing amorphous solid dispersions (ASDs) in preclinical and early clinical development.
Evaluating bioequivalence of an injectable for Type-2 diabetes and weight management
Learn how Syngene supported a global pharma company in conducting human pharmacological studies for Semglutide as an injectable while overcoming clinical and analytical challenges.
Xenografted tumors share comparable fraction unbound and can be surrogated by mouse lung tissue
Publication: Drug Metabolism and Disposition
Ensuring high-quality iPSCs to maximize drug discovery success
Learn the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control of every iPSC batch to maximize drug discovery success.
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, activecontrolled, double-blind trial
Publication: The Lancet
Comparing population level humoral and cellular immunity to SARS Cov 2 in Bangalore- India
Publication: Scientific Reports
Syngene’s Center of Excellence for Oligonucleotides: Early Discovery to cGMP manufacturing services
Our Oligonucleotides facility offers end-to-end services, from early discovery to cGMP manufacturing. Specialty areas include chemically synthesized high-quality modified and non-modified custom oligonucleotide (DNA/RNA); siRNA (single & double-stranded); miRNA (modified and non-modified); antisense oligonucleotides; phosphodiesters and morpholinos; all types of oligo conjugates, and all types of base and custom modifications.